OVERVIEW OF ACTIVITY

Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — clinicians must be well informed of these advances. To bridge the gap between research and patient care, this program features leading oncology investigators debating the merits, applications and limitations of emerging data sets. By providing access to the latest research developments and expert perspectives, this CME program assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Apply the results of recent clinical research defining the bone-protective and anticancer role of adjuvant intravenous bisphosphonates with concomitant endocrine therapy to current treatment decisions.
• Recognize the applications and limitations of biomarker assays and genomic signatures as therapeutic decision-making aids in the management of early breast cancer.
• Develop an algorithm for the treatment of localized hormone receptor-positive breast cancer, addressing disease chronicity relative to the benefits and risks of endocrine therapy.
• Summarize existing research to support alternative doses, formulations and schedules of the commonly used adjuvant and metastatic chemotherapeutic regimens.
• Compare and contrast the efficacy and safety of trastuzumab when combined with anthracycline- and nonanthracycline- containing chemotherapy.
• Appraise the role of lapatinib and other novel anti-HER2 agents in the treatment of trastuzumab-resistant metastatic disease.
• Recall the evidence-based role of bevacizumab in the treatment of advanced breast cancer, and explain the scientific rationale for its ongoing investigation in the adjuvant setting.
• Counsel patients with anthracycline- and taxane-refractory breast cancer about the benefits and risks of further treatment with ixabepilone.
• Identify ongoing clinical trial opportunities for appropriately selected patients with breast cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the CDs and complete the Post-test and Educational Assessment and Credit Form located in our website at ResearchToPractice.com/BCU/ThinkTank.

This program is supported by educational grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology and Sanofi-Aventis.

Home · Search

MODERATOR
Neil Love, MD

A CME Audio Series and Activity

Faculty Disclosures

Editor's Office